🇺🇸 FDA
Patent

US 12310944

Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof

granted A61KA61K31/167A61K31/195

Quick answer

US patent 12310944 (Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof) held by CHINA PHARMACEUTICAL UNIVERSITY expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHINA PHARMACEUTICAL UNIVERSITY
Grant date
Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/167, A61K31/195, A61K31/24, A61K31/277